Table 1.
Baseline clinical characteristics of study population. Data are presented as “mean ± standard deviation” or “absolute value (percentage)”
| Total n = 75 |
Responders n = 53 |
Non Responders n = 22 |
p | |
|---|---|---|---|---|
| Age | 49.5 ± 9.4 | 49.4 ± 9.4 | 49.6 ± 9.6 | 0.93 |
| Gender, female | 53 (71%) | 35 (66%) | 18 (82%) | 0.14 |
| Age at onset (year) | 14.7 ± 7.0 | 14.9 ± 7.2 | 14.2 ± 6.6 | 0.67 |
| Duration of chronic migraine (years) | 12.2 ± 9.3 | 12.4 ± 9.1 | 11.7 ± 8.0 | 0.78 |
| CM | 5 (7%) | 4 (7%) | 1 (5%) | 0.54 |
| CM + MO | 70 (93%) | 49 (93%) | 21 (95%) | 0.67 |
| Migraine days per month | 22.7 ± 5.1 | 22.8 ± 4.8 | 22.4 ± 5.7 | 0.73 |
| Headache days per month | 24.3 ± 4.9 | 24.2 ± 4.9 | 24.5 ± 4.9 | 0.79 |
| Days of acute drug intake per month | 20.5 ± 7.4 | 20.5 ± 7.6 | 20.5 ± 7.1 | 0.99 |
| Acute treatment | 0.74 | |||
| NSAIDs | 13 (18%) | 10 (19%) | 3 (14%) | |
| Triptans | 18 (24%) | 14 (26%) | 4 (18%) | |
| Combination-analgesic drug | 39 (52%) | 26 (49%) | 13 (59%) | |
| Multiple drug classes | 5 (8%) | 3 (6%) | 2 (9%) | |
| Patients on preventive treatment at BP | 41 (55%) | 30 (57%) | 11 (50%) | 0.39 |
| Patients with other pain conditions | 8 (10%) | 7 (13%) | 1 (5%) | 0.42 |
| Average pain severity at BP (NRS score, range 0–10) | 7.4 ± 1.3 | 7.2 ± 1.3 | 7.6 ± 1.2 | 0.15 |
| No. of previously failed preventive treatments | 4.0 ± 1.3 | 3.9 ± 1.4 | 4.1 ± 1.1 | 0.65 |
CM chronic migraine, CM + MO chronic migraine associated to medication overuse, NSAIDs nonsteroidal anti-inflammatory drugs, Combination-analgesic drug formulation combining drugs of two or more classes, each with analgesic effect or acting as adjuvants, BP baseline observation period, NRS Numerical Rating Scale